Abstract: The present invention provides a method for determining the presence of prostate cancer in a subject which method comprises determining the level of expression of one or more markers in a blood sample from the subject, wherein said one or more markers comprise at least one of E2F3, c-met, pRB, EZH2, e-cad, CAXII, CAIX, HIF-1?, Jagged, PIM-1, hepsin, RECK, Clusterin, MMP9, MTSP-1, MMP24, MMP15, IGFBP-2, IGFBP-3, E2F4, caveolin, EF-1A, Kallikrein 2, Kallikrein 3 and PSGR.
Type:
Application
Filed:
November 24, 2005
Publication date:
June 10, 2010
Applicant:
St. George's Enterprises Limited
Inventors:
Christiane Dorothea Fenske, Sabarinath Balachandran Nair, Christodoulos Pipinikas, Nicholas David Carter
Abstract: The present invention relates to peptides, which impair PBX-dependent regulation of gene transcription and thus have utility in the treatment or prevention of disorders in which aberrant cell division occurs.
Type:
Application
Filed:
June 28, 2006
Publication date:
November 19, 2009
Applicant:
ST. GEORGE'S ENTERPRISES LIMITED
Inventors:
Richard George Leonard Morgan, Jastinder Sohal
Abstract: An eyedrop composition comprising a solution of naloxone hydrochloride in a mixture of water and at least one pharmaceutically acceptable polyhydric alcohol which is stable over long periods of time and is useful in opioid addiction testing